Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.

Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H.

Cancer. 2010 Aug 15;116(16):3830-4. doi: 10.1002/cncr.25247.

PMID:
20564137
[PubMed - indexed for MEDLINE]
Free Article
2.

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.

Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP.

Cancer. 2007 Jan 15;109(2):265-73.

PMID:
17133405
[PubMed - indexed for MEDLINE]
Free Article
3.

Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.

Yi JH, Huh J, Kim HJ, Kim SH, Kim SH, Kim KH, Do YR, Mun YC, Kim H, Kim MK, Kim HJ, Kim T, Kim DD.

Ann Hematol. 2013 Apr;92(4):459-69. doi: 10.1007/s00277-012-1635-7. Epub 2012 Dec 23.

PMID:
23262795
[PubMed - indexed for MEDLINE]
4.

Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.

Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):711-5. doi: 10.1016/j.clml.2013.07.007. Epub 2013 Sep 17.

PMID:
24054159
[PubMed - indexed for MEDLINE]
5.

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.

Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.

Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10. Review.

PMID:
20507806
[PubMed - indexed for MEDLINE]
Free Article
6.

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.

Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A.

Br J Haematol. 2001 Aug;114(2):349-57.

PMID:
11529854
[PubMed - indexed for MEDLINE]
7.

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.

J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.

PMID:
21483003
[PubMed - indexed for MEDLINE]
Free Article
8.

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.

Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP.

Cancer. 2007 Mar 15;109(6):1133-7.

PMID:
17315156
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP.

Blood. 2007 Jan 1;109(1):52-7. Epub 2006 Aug 1.

PMID:
16882708
[PubMed - indexed for MEDLINE]
Free Article
10.

Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.

Iastrebner M, Jang JH, Nucifora E, Kim K, Sackmann F, Kim DH, Orlando S, Jung CW, Basquiera A, Klein G, Santini F, Bernard HI, Korin J, Taborda G.

Leuk Lymphoma. 2010 Dec;51(12):2250-7. doi: 10.3109/10428194.2010.524324. Epub 2010 Oct 7.

PMID:
20929328
[PubMed - indexed for MEDLINE]
11.

A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome.

Lee JH, Jang JH, Park J, Park S, Joo YD, Kim YK, Kim HG, Choi CW, Kim SH, Park SK, Park E, Min YH.

Haematologica. 2011 Oct;96(10):1441-7. doi: 10.3324/haematol.2011.046078. Epub 2011 Jun 9.

PMID:
21659363
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.

Joeckel TE, Lübbert M.

Semin Hematol. 2012 Oct;49(4):330-41. doi: 10.1053/j.seminhematol.2012.08.001. Review.

PMID:
23079063
[PubMed - indexed for MEDLINE]
13.

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.

Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):592-6. doi: 10.1016/j.clml.2013.05.004. Epub 2013 Jun 20.

PMID:
23790798
[PubMed - indexed for MEDLINE]
14.

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.

Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, Kantarjian H.

Cancer. 2007 Feb 15;109(4):713-7.

PMID:
17219444
[PubMed - indexed for MEDLINE]
Free Article
15.

Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.

Li X, Chang C, He Q, Xu F, Zhang Q, Wu L, Su J, Zhang X, Zhou L, Wu D, Song L, Zhang Z.

Leuk Res. 2013 Nov;37(11):1516-21. doi: 10.1016/j.leukres.2013.09.006. Epub 2013 Sep 18.

PMID:
24084368
[PubMed - indexed for MEDLINE]
16.

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.

Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):131-8. doi: 10.1016/j.clml.2012.11.001. Epub 2012 Dec 21.

PMID:
23260600
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.

Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H.

J Clin Oncol. 2013 Jul 10;31(20):2548-53. doi: 10.1200/JCO.2012.44.6823. Epub 2013 Jun 3.

PMID:
23733767
[PubMed - indexed for MEDLINE]
Free Article
18.

Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.

Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E.

Clin Ther. 2010 Dec;32(14):2444-56. doi: 10.1016/j.clinthera.2010.12.003.

PMID:
21353113
[PubMed - indexed for MEDLINE]
19.

Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Voso MT, Breccia M, Lunghi M, Poloni A, Niscola P, Finelli C, Bari A, Musto P, Zambello R, Fianchi L, Alimena G, Leone G.

Eur J Haematol. 2013 Apr;90(4):345-8. doi: 10.1111/ejh.12079. Epub 2013 Feb 28.

PMID:
23336938
[PubMed - indexed for MEDLINE]
20.

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.

Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias.

Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894.

PMID:
20151429
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk